{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:57:09Z","timestamp":1786550229329,"version":"build-2736575974"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geburtshilfe Frauenheilkd"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>The publication of two large randomized studies \u2013 the ENGOT-EN-6-NSGO\/GOG-3031\/RUBY trial and the NRG-GY018 trial \u2013 which investigated combining chemotherapy with immunotherapy to treat\n            patients with primary advanced or recurrent endometrial cancer (EC) has transformed the clinical study landscape in terms of first-line therapy for affected patients and has set a new\n            standard of therapy. In the ENGOT-EN-6-NSGO\/GOG-3031\/RUBY trial, the addition of dostarlimab to standard chemotherapy with carboplatin and paclitaxel resulted in<\/jats:p><jats:p>In the NRG-GY018 trial, the addition of pembrolizumab to standard chemotherapy with carboplatin and paclitaxel resulted in<\/jats:p><jats:p>As expected, the effect in both trials was much more pronounced in the group of patients with dMMR\/MSI-high tumors. According to the assessment of the Uterus Organ Commission of the AGO,\n            all patients with dMMR\/MSI-high tumors should receive chemoimmunotherapy and all patients with pMMR\/MSI-low tumors who meet the inclusion criteria of the two trials discussed here may have\n            chemoimmunotherapy. For dostarlimab this means:<\/jats:p><jats:p>For pembrolizumab this means:<\/jats:p>","DOI":"10.1055\/a-2145-1545","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:53:09Z","timestamp":1694559189000},"page":"1095-1101","source":"Crossref","is-referenced-by-count":7,"title":["Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on the Use of Primary Chemoimmunotherapy to Treat Patients with Locally Advanced\n          or Recurrent Endometrial Cancer"],"prefix":"10.1055","volume":"83","author":[{"given":"Clemens","family":"Tempfer","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsfrauenklinik der Ruhr Universit\u00e4t Bochum, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brucker","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Frauenklinik T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Juhasz-Boess","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Frauenheilkunde, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mallmann","sequence":"additional","affiliation":[{"name":"Frauenklinik \u2013 Uniklinik K\u00f6ln, K\u00f6ln, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Steiner","sequence":"additional","affiliation":[{"name":"Frauenklinik, GPR Klinikum R\u00fcsselsheim, R\u00fcsselsheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Denschlag","sequence":"additional","affiliation":[{"name":"Frauenklinik, Hochtaunus Kliniken, Bad Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[{"name":"Frauenklinik, Medizinische Hochschule Hannover, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallwiener","sequence":"additional","affiliation":[{"name":"Frauenklinik (Zentrum), Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Uterus Commission of the AGO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"M R Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"R N Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","article-title":"Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis","volume":"118","author":"J N Barlin","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"C L Creutzberg","year":"2003","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.brachy.2017.07.002","article-title":"Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy","volume":"16","author":"C H Chapman","year":"2017","journal-title":"Brachytherapy"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1006\/gyno.2000.6005","article-title":"Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy","volume":"79","author":"T Y Ng","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"2012","key":"ref8","first-page":"CD003915","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma","author":"C L Vale","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"D S Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","author":"J S Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer","volume":"380","author":"D Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"M E Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3\n          trial","volume":"19","author":"S M de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3\n          trial","volume":"20","author":"S M de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3\u2009Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Geburtshilfe und Frauenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2145-1545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:54:04Z","timestamp":1694559244000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2145-1545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":14,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2023,9,12]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2145-1545","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0016-5751","1438-8804"],"issn-type":[{"value":"0016-5751","type":"print"},{"value":"1438-8804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}